[go: up one dir, main page]

HUE047997T2 - Oxa diazaspiro vegyület fájdalom elleni hatással - Google Patents

Oxa diazaspiro vegyület fájdalom elleni hatással

Info

Publication number
HUE047997T2
HUE047997T2 HUE16784795A HUE16784795A HUE047997T2 HU E047997 T2 HUE047997 T2 HU E047997T2 HU E16784795 A HUE16784795 A HU E16784795A HU E16784795 A HUE16784795 A HU E16784795A HU E047997 T2 HUE047997 T2 HU E047997T2
Authority
HU
Hungary
Prior art keywords
oxa
activity against
against pain
diazaspiro compounds
diazaspiro
Prior art date
Application number
HUE16784795A
Other languages
English (en)
Inventor
Marina Virgili-Bernado
Carmen Almansa-Rosales
Carlos Alegret-Molina
Original Assignee
Esteve Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals Sa filed Critical Esteve Pharmaceuticals Sa
Publication of HUE047997T2 publication Critical patent/HUE047997T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HUE16784795A 2015-10-23 2016-10-21 Oxa diazaspiro vegyület fájdalom elleni hatással HUE047997T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15382523 2015-10-23

Publications (1)

Publication Number Publication Date
HUE047997T2 true HUE047997T2 (hu) 2020-05-28

Family

ID=54364221

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16784795A HUE047997T2 (hu) 2015-10-23 2016-10-21 Oxa diazaspiro vegyület fájdalom elleni hatással

Country Status (31)

Country Link
US (1) US10689398B2 (hu)
EP (1) EP3365346B1 (hu)
JP (1) JP6884973B2 (hu)
KR (1) KR20180073638A (hu)
CN (1) CN108349998B (hu)
AR (1) AR106448A1 (hu)
AU (1) AU2016343551A1 (hu)
BR (1) BR112018007269A2 (hu)
CA (1) CA2999925A1 (hu)
CO (1) CO2018004803A2 (hu)
CY (1) CY1122708T1 (hu)
DK (1) DK3365346T3 (hu)
ES (1) ES2775522T3 (hu)
HR (1) HRP20200309T1 (hu)
HU (1) HUE047997T2 (hu)
IL (1) IL258370A (hu)
LT (1) LT3365346T (hu)
MA (1) MA43158B1 (hu)
ME (1) ME03636B (hu)
MX (1) MX2018004777A (hu)
PH (1) PH12018500682A1 (hu)
PL (1) PL3365346T3 (hu)
PT (1) PT3365346T (hu)
RS (1) RS59956B1 (hu)
RU (1) RU2018118399A (hu)
SG (1) SG11201802988XA (hu)
SI (1) SI3365346T1 (hu)
SM (1) SMT202000128T1 (hu)
TN (1) TN2018000091A1 (hu)
TW (1) TW201731853A (hu)
WO (1) WO2017067664A1 (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201615643A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
US10689398B2 (en) 2015-10-23 2020-06-23 Esteve Pharmaceuticals, S.A. OXA-Diazaspiro compounds having activity against pain

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481942A (en) 1968-09-06 1969-12-02 Smithkline Corp Oxa-diazaspiro(4.5)decane compounds
US4353900A (en) 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
WO1993013101A1 (fr) * 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro
US6114541A (en) 1997-03-10 2000-09-05 Hoffmann-La Roche Inc. Method for the preparation of α-Bromo-Lactam derivatives
DE60236206D1 (de) 2001-12-28 2010-06-10 Acadia Pharm Inc Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
EP2762475A1 (en) * 2003-11-07 2014-08-06 Novartis Vaccines and Diagnostics, Inc. Pharmaceutically acceptable salts of quinolinone compounds and their medical use
EP1634873A1 (en) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
EP1829869A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands
WO2007124136A1 (en) 2006-04-19 2007-11-01 Acadia Pharmaceuticals, Inc. Use of 4-amino-piperidines for treating sleep disorders
EP1847542A1 (en) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
CA2679530C (en) 2007-03-01 2012-09-25 Mitsubishi Tanabe Pharma Corporation Benzimidazole compound and pharmaceutical use thereof
EP1982714A1 (en) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-amines
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
JP2010538003A (ja) 2007-08-29 2010-12-09 グラクソスミスクライン エルエルシー チアゾールおよびオキサゾールキナーゼ阻害薬
EP2070933A1 (en) 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Tricyclic triazolic compounds
WO2009098448A1 (en) 2008-02-06 2009-08-13 Astrazeneca Ab Compounds
CN102668581A (zh) 2009-10-25 2012-09-12 Lg电子株式会社 用于处理广播节目信息的方法及广播接收器
EP2686325B1 (en) * 2011-03-14 2016-12-14 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
WO2012125813A1 (en) 2011-03-16 2012-09-20 Access Business Group International Llc Humidifier with ultraviolet disinfection
ES2608053T3 (es) 2011-08-19 2017-04-05 Glaxosmithkline Intellectual Property (No. 2) Limited Inhibidores de ácido graso sintasa
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JP2017100951A (ja) 2014-04-04 2017-06-08 大正製薬株式会社 オキサゾリジノン及びオキサジナノン誘導体
TW201615643A (zh) * 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
TWI685497B (zh) 2014-06-02 2020-02-21 西班牙商伊史帝夫製藥公司 具有多重模式抗疼痛活性的１-氧雜-４,９-二氮雜螺十一烷化合物之烷基衍生物
TW201615642A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性的１－氧雜－４，９－二氮雜螺十一烷化合物之醯胺衍生物
MX2017006513A (es) 2014-11-21 2018-04-11 Esteve Labor Dr Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
US10689398B2 (en) 2015-10-23 2020-06-23 Esteve Pharmaceuticals, S.A. OXA-Diazaspiro compounds having activity against pain

Also Published As

Publication number Publication date
MX2018004777A (es) 2018-06-19
TW201731853A (zh) 2017-09-16
EP3365346A1 (en) 2018-08-29
RU2018118399A3 (hu) 2020-01-31
US20190002475A1 (en) 2019-01-03
TN2018000091A1 (en) 2019-07-08
WO2017067664A9 (en) 2017-06-29
IL258370A (en) 2018-05-31
SI3365346T1 (sl) 2020-04-30
HRP20200309T1 (hr) 2020-06-12
ES2775522T3 (es) 2020-07-27
SG11201802988XA (en) 2018-05-30
WO2017067664A1 (en) 2017-04-27
RS59956B1 (sr) 2020-03-31
RU2018118399A (ru) 2019-11-25
BR112018007269A2 (pt) 2018-10-30
CN108349998A (zh) 2018-07-31
ME03636B (me) 2020-07-20
JP2018531263A (ja) 2018-10-25
CO2018004803A2 (es) 2018-07-19
EP3365346B1 (en) 2019-12-04
PL3365346T3 (pl) 2020-06-01
JP6884973B2 (ja) 2021-06-09
CY1122708T1 (el) 2021-03-12
SMT202000128T1 (it) 2020-05-08
MA43158B1 (fr) 2020-03-31
AU2016343551A1 (en) 2018-04-19
CN108349998B (zh) 2021-10-29
CA2999925A1 (en) 2017-04-27
AR106448A1 (es) 2018-01-17
PT3365346T (pt) 2020-03-05
US10689398B2 (en) 2020-06-23
LT3365346T (lt) 2020-04-10
PH12018500682A1 (en) 2018-10-01
KR20180073638A (ko) 2018-07-02
DK3365346T3 (da) 2020-03-09

Similar Documents

Publication Publication Date Title
IL254721A0 (en) 1-cyano-pyrrolidine compounds as usp30 inhibitors
ZA201700670B (en) Compounds active towards bromodomains
GB201407288D0 (en) Activity monitors
GB201502137D0 (en) Treatment
GB201616839D0 (en) Therapeutic compounds
GB2538043B (en) Activity monitor
GB201522243D0 (en) Treatment
HUE043954T2 (hu) Szklerózis multiplex kezelése
GB201601703D0 (en) Therapeutic compounds
PT3359556T (pt) Modulação da atividade de citocinas gama-c
GB201502412D0 (en) Therapeutic use
GB201617339D0 (en) Therapeutic compounds
GB201604658D0 (en) Treatment for pain
GB201508841D0 (en) Treatment
IL258370A (en) Oxa-diazaspiro compounds with analgesic activity
PT3365338T (pt) Derivados de morfolina substituídos tendo atividade contra a dor
GB201506786D0 (en) Therapeutic use
GB201503008D0 (en) Treatment
PT3365345T (pt) Composto de oxa- azaespiro tendo atividade contra a dor
GB201511410D0 (en) Pain supressars
GB2555225B (en) Hydrocarbon-contamination treatment unit
GB201505205D0 (en) Treatment for pain
GB201504688D0 (en) Treatment for pain
GB201609790D0 (en) Therapeutic compounds
GB201609737D0 (en) Therapeutic compounds